Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 589 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07703735Enrolling by invitation
Survival after ABO-mismatch living donor liver transplant for liver cancer
This trial looks at how well patients with liver cancer do after receiving a living donor liver transplant that is not the same blood type. It compares survival and cancer return for these patients.
Ages 18 years+ - NCT05143619Recruiting
Teaching liver cancer diagnosis to radiologists worldwide
This study looks at whether a “teaching the teachers” approach improves how radiologists understand and apply liver cancer (HCC) diagnosis guidelines. It may help by standardizing how liver imaging results are interpreted across different countries and practice settings.
Houston, TexasAges Any age - NCT05844046RecruitingPhase 2
Triple drug treatment for advanced liver cancer that can’t be removed
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
MunichAges 18 years+ - NCT05953961Recruiting
90Y radiation compared with microwave ablation for small liver cancer
This trial compares two procedures to treat a small, single liver tumor that cannot be surgically removed. It aims to see which treatment works better for people with low blood protein (albumin), which can affect healing and outcomes.
New Orleans, LouisianaAges 18 years+ - NCT06070636Recruiting
Triple therapy for aggressive liver cancer
This trial tests a combination of three treatments for a specific type of aggressive liver cancer called infiltrative hepatocellular carcinoma (HCC). It combines targeted therapy (lenvatinib), immunotherapy (sintilimab), and a procedure that delivers chemotherapy directly to the liver (bTAE-HAIC). The goal is to see if this triple approach works better for people with large tumors or those that have spread to the portal vein.
Guangzhou, GuangdongAges 18–75 - NCT03942328RecruitingPhase 1/Phase 2
Immune cell vaccine plus checkpoint treatment after liver radiation
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
Rochester, MinnesotaAges 18 years+ - NCT06379256Recruiting
Liver cancer radiation and immune response study
This trial studies how radiation therapy affects the immune system and outcomes in people with liver cancer. It may help doctors understand better ways to treat the disease.
Taoyuan City, TaiwanAges 18 years+ - NCT06478927Recruiting
Palbociclib for advanced liver cancer after other treatments
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
Zhengzhou, HenanAges 18–75 - NCT06653062Recruiting
Blood test to watch for liver cancer return
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
Wuhan, HubeiAges 18 years+ - NCT06860490RecruitingPhase 2
Liver cancer trial: HAIC plus immunotherapy and anti-angiogenesis
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07170345Recruiting
AI to detect hidden spread in liver cancer from scans
This trial uses a computer program to help doctors find signs of microscopic tumor spread in blood vessels (microvascular invasion) from liver cancer images. It aims to improve treatment planning for patients who are having surgery.
Fuzhou, FujianAges 18–18 - NCT07186010Recruiting
Immune therapy biomarkers in advanced liver cancer
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
Seoul, Song-paAges 19 years+ - NCT07331883RecruitingPhase 2
Sintilimab and bevacizumab after surgery for ruptured liver cancer
This trial tests whether combining two immune-based drugs (sintilimab and a bevacizumab biosimilar) after surgery can prevent liver cancer from returning in people whose tumor had ruptured. It’s for patients who have had a complete surgical removal of a ruptured hepatocellular carcinoma and are now cancer-free on imaging.
Sanming, FujianAges 18–75 - NCT07265271Recruiting
Study to detect liver cancer early using blood tests
This study is looking for people with or without liver cancer to test a new way to find liver cancer early using blood or tissue samples. It aims to help catch the disease sooner.
Duarte, CaliforniaAges 18 years+ - NCT07391839RecruitingPhase 1
MDN-001 injection for liver cancer that can't be surgically removed
This trial tests an injection called MDN-001 for people with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or other local treatments. The goal is to see if it is safe and effective for patients whose cancer has not spread outside the liver.
Hefei, AnhuiAges 18–80 - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other solid tumors
This trial tests an oral drug called TYRA-430 for people with advanced liver cancer (HCC) or other solid tumors that have changes in the FGF/FGFR pathway. It aims to see how safe the drug is and whether it can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT06632093Recruiting
Combination therapy for advanced liver cancer after standard treatment fails
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
Shenyang, LiaoningAges 18–75 - NCT07268131Recruiting
TITAN-HCC: Testing immunotherapy plus TACE for liver cancer beyond standard criteria
This trial tests a combination of an immunotherapy drug (QL1706) and a liver-directed procedure (TACE) before and after surgery for people with liver cancer that is larger or more advanced than the usual transplant criteria. The goal is to see if this approach can help shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06796803RecruitingPhase 2/Phase 3
Combination therapy before surgery for liver cancer
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Harbin, HeilongjiangAges 18–75 - NCT04340986Recruiting
Group study for bile duct or liver cancer patients
This study follows people with bile duct cancer or certain liver cancers to better understand their disease. You might be included if you meet the diagnosis and basic participation requirements.
ParisAges 18 years+ - NCT04587739RecruitingPhase 1
Radiation before surgery for a single liver tumor
This early feasibility study tests a radiation plan given before surgery for hepatocellular carcinoma (a type of liver cancer) to see if it’s safe and doable. It may help shrink or control the tumor before an operation that aims to fully remove it.
LilleAges 18–70 - NCT05223816RecruitingPhase 2
Tested drug shots for advanced liver and bile duct cancers
This Phase 2 study tests a drug called VG161 given by injection into liver tumors, either alone or together with nivolumab. It aims to see how well it works and whether it is safe for people with advanced hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).
Phoenix, ArizonaAges 18 years+
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 589 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.